These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12456630)

  • 21. Estrogen replacement therapy in combination with continuous intrauterine progestin administration reduces the amount of circulating oxidized LDL in postmenopausal women: dependence on the dose of progestin.
    Ahotupa M; Rauramo I; Vasankari TJ; Skouby SO; Hakonen T
    Ann Med; 2004; 36(4):278-84. PubMed ID: 15224654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors.
    Chen FP; Lee N; Soong YK; Huang KE
    Menopause; 2001; 8(5):347-52. PubMed ID: 11528361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?
    McKenzie J; Jaap AJ; Gallacher S; Kelly A; Crawford L; Greer IA; Rumley A; Petrie JR; Lowe GD; Paterson K; Sattar N
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):682-9. PubMed ID: 14974908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group.
    Bjarnason K; Cerin A; Lindgren R; Weber T
    Maturitas; 1999 Aug; 32(3):161-70. PubMed ID: 10515673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: a randomized, double-blind, controlled trial.
    Cravioto MD; Durand-Carbajal M; Jiménez-Santana L; Lara-Reyes P; Seuc AH; Sánchez-Guerrero J
    Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1654-63. PubMed ID: 22127965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemodynamic and metabolic effects of estrogen plus progestin therapy in hypertensive postmenopausal women treated with an ACE-inhibitor or a diuretic.
    Posadzy-Malaczynska A; Rajpold K; Woznicka-Leskiewicz L; Marcinkowska J
    Clin Res Cardiol; 2015 Jan; 104(1):38-50. PubMed ID: 25216597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mammographic density changes during different postmenopausal hormone replacement therapies.
    Sendağ F; Coşan Terek M; Ozşener S; Oztekin K; Bilgin O; Bilgen I; Memiş A
    Fertil Steril; 2001 Sep; 76(3):445-50. PubMed ID: 11532462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT.
    Boon J; Scholten PC; Oldenhave A; Heintz AP
    Maturitas; 2003 Sep; 46(1):69-77. PubMed ID: 12963171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women.
    Sidelmann JJ; Skouby SO; Vitzthum F; Schwarz H; Jespersen J
    Climacteric; 2010 Aug; 13(4):340-6. PubMed ID: 20222844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study.
    Koskela-Niska V; Lyytinen H; Riska A; Pukkala E; Ylikorkala O
    Climacteric; 2013 Feb; 16(1):48-53. PubMed ID: 22640598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.
    Roach RE; Lijfering WM; Helmerhorst FM; Cannegieter SC; Rosendaal FR; van Hylckama Vlieg A
    J Thromb Haemost; 2013 Jan; 11(1):124-31. PubMed ID: 23136837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens.
    Biglia N; Ambroggio S; Ponzone R; Sgro L; Ujcic E; Dato FA; Sismondi P
    Maturitas; 2003 Aug; 45(4):283-91. PubMed ID: 12927315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women.
    Seed M; Sands RH; McLaren M; Kirk G; Darko D
    Fam Pract; 2000 Dec; 17(6):497-507. PubMed ID: 11120722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy.
    Agrawal R; Prelevic G; Conway GS; Payne NN; Ginsburg J; Jacobs HS
    Fertil Steril; 2000 Jan; 73(1):56-60. PubMed ID: 10632412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?
    Brosnan JF; Sheppard BL; Norris LA
    Thromb Haemost; 2007 Apr; 97(4):558-65. PubMed ID: 17393018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
    Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
    Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.